Summary
Johnson & Johnson's 2006 10-K filing, reported in early 2007, showcases a robust healthcare conglomerate with strong performance across its three core segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The company demonstrated significant investment in research and development, totaling $7.1 billion in 2006, underscoring its commitment to innovation and future growth. A notable event during the year was the acquisition of Pfizer's Consumer Healthcare business, which expanded the company's brand portfolio in areas like oral care and cold/flu remedies. Despite facing generic competition for some key pharmaceutical products like DURAGESIC®/Fentanyl Transdermal, the company's diversified product pipeline and ongoing patent protection for other major drugs, such as RISPERDAL® and TOPAMAX®, suggest continued resilience. J&J's widespread global presence and decentralized management structure further support its operational strength and ability to adapt to diverse market conditions.
Key Highlights
- 1Johnson & Johnson operates across three primary segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics, demonstrating a diversified healthcare business model.
- 2The company made a significant strategic move by acquiring Pfizer's Consumer Healthcare business in Q4 2006, bolstering its presence in the consumer health market with well-known brands.
- 3Research and development spending was substantial, reaching $7.1 billion in 2006, reflecting a strong commitment to innovation and new product development.
- 4Key pharmaceutical products like RISPERDAL® and TOPAMAX® have patent expirations approaching in late 2007 and 2008, respectively, with potential pediatric extensions that could extend exclusivity.
- 5The company experienced generic competition for DURAGESIC®/Fentanyl Transdermal, leading to a sales decline, but this was partially mitigated by limited near-term generic competition for EPREX®.
- 6Johnson & Johnson maintains a vast global footprint with operations in 56 countries and 148 manufacturing facilities worldwide.
- 7The company reported effective disclosure controls and procedures and internal control over financial reporting as of December 31, 2006, with the exclusion of the recently acquired Pfizer Consumer Healthcare business from the internal control assessment due to its recent integration.